FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Cash-and-Carry King Kirsh Caps Second Act With $29 Billion Sale
Russia’s top general Gerasimov says forces are advancing around Kostiantynivka on multiple...
Atos Q1 revenue falls; narrows FY outlook on weak start
Most currencies steady as markets focus on US-Iran talks, NZ dollar gains
JPM To Invest In Europe And UK In Expanded $1.5T Security Initiative – FT...
Beyond Meat Stock Is Trending Overnight: Here's What's Going On
China’s lead output declines 11.4% from a year earlier to 652,000 metric tons in March, according to...
Tesla (TSLA) Stock: New V2X Program Turns EVs into Home Backup and Income Sources
GLJ Research Initiates Coverage on Legence Corp with Buy Rating
Trump's Board of Peace Engages with DP World on Gaza Reconstruction
Wihlborgs reports 10% rental income growth in first quarter
Exclusive-SpaceX president Shotwell earned $85 million last year, document shows
Bank of China Group Investment’s CNY notes are rated ‘A’ by Fitch....
Wall Street Banks Flag Risks for Kenya’s Shilling as War Rages On
Pakistan’s Bid to Mediate US‑Iran Talks Amid Uncertainty
DONALD TRUMP’S ‘BOARD OF PEACE’ HELD TALKS WITH DP WORLD OVER GAZA RECONSTRUCTION- FT...
Tim Cook Steps Down as Apple CEO After 15 Years
Baird Downgrades Albemarle Amid Concerns Over Lithium Outlook
Boston Scientific Set to Release Q1 Earnings Report
Vistra's Share Price Sees Significant Increase Amid Mixed Performance
Semiconductor Stocks Surge Amid Strong Market Performance
South Korea to Repatriate Remains of 12 Chinese Troops from Korean War
GLJ Research starts coverage on Legence Corp with a buy rating and $99 price target....
Bonds are not buying it
US positive on Iran deal but talks still uncertain as ceasefire end nears
OPmobility reports 0.4% revenue fall as autos industry weakens
Cathie Wood's ARK Invest Backs SpaceX's $1.75 Trillion Valuation Ahead Of IPO: 'Grounded In Plausible…'
Apple's Incoming CEO John Ternus Faces AI Strategy Challenge
EUR/USD FX Option Expiries Set for April 21
Trump Claims Operation Midnight Hammer Destroyed Iran's Nuclear Sites
Victory Giant Shares Surge 60% in Hong Kong Market Debut
JGB re-offer auction records a peak yield spread of -0.031%....
Japan lifts ban on lethal arms exports-FT...
The China Show 4/21/2026 (Video)
Broadcom Launches AI-Driven Fraud Detection Product for Payments
Yum! Brands Reports Mixed Short-Term Stock Performance
United Rentals Set to Release Q1 Earnings This Wednesday
Trump Discusses Challenges of Extracting Nuclear Materials from Iran
Magnitude 6 Earthquake Strikes Off Timor Island
RBC trims Ameriprise Financial Inc target price to $560 versus $605 previously....
Apple Asian supplier shares mixed on CEO succession plans
Rigaku shares hit record high on Onto Innovation alliance, stake deal
Morning Bid: Markets long for peace, prepare for Warsh
Oman opens bank in Angola to boost African trade ties
MSCI boots Indonesian tycoon-owned stocks from indices
London Tube Strike Set to Cause Travel Chaos for Commuters
Goldman Sachs Signals Uncertainty for Fed Rate Cuts in 2026
Iran Claims US Attack on Commercial Vessel, Calls for Crew Release
Hong Kong Flight Capacity Set to Rise 10% on China, Korea Demand
Morgan Stanley Increases Price Target for Vertex Pharmaceuticals
Morgan Stanley has raised its price target for Vertex Pharmaceuticals to $612, up from a previous target of $596. The firm has maintained an Overweight rating on the company's shares, indicating a positive outlook for the stock.
This adjustment comes as Morgan Stanley updated its models for the biopharma sector, taking into account recent IQVIA trends and intra-quarter updates. The changes are made in anticipation of the upcoming Q1 earnings report from Vertex and other companies in the group.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News